Denali Capital Acquisition said $50,000 was deposited into its trust to extend the SPAC’s completion deadline to March 11, following shareholder approval in January of a merger with Longevity Biomedical.
Redemptions have removed most of the SPAC’s trust, although Longevity Biomedical in August agreed to waive the deal’s $30 million cash closing condition.
Longevity is focused on advancing new technologies across therapeutics, health monitoring and digital health solutions “to increase human health span.” Read more.
